**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 44797**

**Manuscript Type: MINIREVIEWS**

**MicroRNAs contribute to ATP-binding cassette transporter- and autophagy-mediated chemoresistance in hepatocellular carcinoma**

Espelt *et al*. miRNA impact on hepatocellular carcinoma chemoresistance

María V Espelt, María L Bacigalupo, Pablo Carabias, María F Troncoso

**María V Espelt, María L Bacigalupo, Pablo Carabias, María F Troncoso,** Facultad de Farmacia y Bioquímica, Instituto de Química y Fisicoquímica Biológicas, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, Buenos Aires C1113AAD, Argentina

**ORCID number**: María V Espelt (0000-0002-0388-7853); María L Bacigalupo (0000-0003-4114-2622); Pablo Carabias ( 0000-0002-2709-9165); María F Troncoso (0000-0002-4919-9976).

**Author contributions:** Espelt MV contributed to literature search, manuscript drafting, table composing and final revision of the article; Bacigalupo ML contributed to manuscript drafting, table composing and final revision of the article; Carabias P contributed to final revision of the article; Troncoso MF contributed to the study idea and design, manuscript drafting, table composing and final revision of the article.

**Supported by** Agencia Nacional de Promoción Científica y Tecnológica-Fondo para la Investigación Científica y Tecnológica, No. PICT-2014-3216 (to Espelt MV); CONICET, No. PIP-647; UBA, No. Programación Científica 2016-2019, No. 20020150100005BA; and ANPCyT-FONCYT, No. PICT-2016-1139 (all to Troncoso MF).

**Conflict-of-interest statement**: The authors declare no conflict of interest related to this publication.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: María Fernanda Troncoso, PhD,** Facultad de Farmacia y Bioquímica, Instituto de Química y Fisicoquímica Biológicas, Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina. fernanda@qb.ffyb.uba.ar

**Telephone:** +54-11-52874122

**Received:** November 28, 2018

**Peer-review started:** November 28, 2018

**First decision:** January 23, 2019

**Revised:** February 21, 2019

**Accepted:** March 24, 2019

**Article in press:** March 25, 2019

**Published online:** April 27, 2019

**Abstract**

Hepatocellular carcinoma (HCC) has an elevated mortality rate, largely because of high recurrence and metastasis. Additionally, the main obstacle during treatment of HCC is that patients usually develop resistance to chemotherapy. Cancer drug resistance involves many different mechanisms, including alterations in drug metabolism and processing, impairment of the apoptotic machine, activation of cell survival signaling, decreased drug sensitivity and autophagy, among others. Nowadays, miRNAs are emerging as master regulators of normal physiology- and tumor-related gene expression. In HCC, aberrant expression of many miRNAs leads to chemoresistance. Herein, we particularly analyzed miRNA impact on HCC resistance to drug therapy. Certain miRNAs target ABC (ATP-binding cassette) transporter genes. As most of these miRNAs are downregulated in HCC, transporter levels increase and intracellular drug accumulation decrease, turning cells less sensitive to death. Others miRNAs target autophagy-related gene expression, inhibiting autophagy and acting as tumor suppressors. Nevertheless, due to its downregulation in HCC, these miRNAs do not inhibit autophagy or tumor growth and, resistance is favored. Concluding, modulation of ABC transporter and/or autophagy-related gene expression or function by miRNAs could be determinant for HCC cell survival under chemotherapeutic drug treatment. Undoubtedly, more insights on the biological processes, signaling pathways and/or molecular mechanisms regulated by miRNAs are needed. Anyway, miRNA-based therapy together with conventional chemotherapeutic drugs has a great future in cancer therapy.

**Key words:** Hepatocellular carcinoma; Chemoresistance; ABC transporter; autophagy; miRNA

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The main obstacle during treatment of hepatocellular carcinoma (HCC) is resistance to chemotherapy. We analyzed microRNAs (miRNAs) impact on HCC chemoresistance. Certain miRNAs target ABC transporter genes. As most of these miRNAs are downregulated in HCC, transporter levels increase and intracellular drug accumulation decrease, turning cells less sensitive to death. Others miRNAs target autophagy-related gene expression, inhibiting autophagy and acting as tumor suppressors. Nevertheless, due to its downregulation in HCC, these miRNAs do not inhibit autophagy or tumor growth and, resistance is favored. ABC transporter and/or autophagy-related gene expression modulated by miRNAs affect HCC cell survival under chemotherapy.

Espelt MV, Bacigalupo ML, Carabias P, Troncoso MF. MicroRNAs contribute to ATP-binding cassette transporter- and autophagy-mediated chemoresistance in hepatocellular carcinoma. *World J Hepatol* 2019; 11(4): 344-358

**URL:** https://www.wjgnet.com/1948-5182/full/v11/i4/344.htm

**DOI:** https://dx.doi.org/10.4254/wjh.v11.i4.344

**INTRODUCTION**

Hepatocellular carcinoma (HCC) accounts for around 80%-90% of liver cancer. It’s the fifth most common cancer worldwide and the third cancer-related death cause. In general, HCC develops in a background of cirrhosis. The main factors that contribute to this tumor are infections with hepatitis B or C virus, alcohol abuse and non-alcoholic fatty liver disease[1]. Despite the development of early detection methods, 80% of HCC patients are diagnosed at a stage of the disease so advanced that the patient’s survival is just of about few months[2]. When HCC is diagnosed at early stages the most effective approaches are partial hepatectomy or liver transplantation, however in most patients the tumor is not detected promptly or it is hard to find a compatible donor. In intermediate stages, transarterial chemoembolization is the treatment of choice[3]. For patients with unresectable HCC, sorafenib oral administration slightly improves survival[4]. Even the ones who qualify for surgery have a modest improvement in the survival because of its high rate of recurrence, occurring in more than 90% of patients[2].

Treatment with anti-cancer drugs (chemotherapy) can destroy tumor cells helping patients to control cancer growth. Some of these drugs to treat HCC are 5-fluorouracil (5-FU), cisplatin, doxorubicin[5], paclitaxel and the multitarget tyrosine kinase inhibitor sorafenib. But unfortunately, liver cancer patients usually develop drug resistance to chemotherapy[6]. Cancer drug resistance is a multifactorial phenomenon involving many different mechanisms such as gene mutation, DNA repair pathway aberrations, impairment of the apoptotic machine, alterations in drug metabolism and processing, activation of cell survival signaling and escape of drug sensitivity, autophagy, epigenetic regulation, altered lipid metabolism and tumor microenvironment participation[2]. Among these mechanisms, modifications in drug uptake or efflux produce a diminished intracellular drug concentration, leading to tumor cell survival and resistance to death. Until some years ago, the reduction of intracellular drug concentration was thought to be the only important mechanism for resistance. Nevertheless, many other processes have been appeared to be involved more lately. Autophagy is one of these novel processes that also contribute to tumor chemotherapy resistance; moreover, autophagy inhibitors are used to sensitize different cancers to chemotherapy. Under this scenario, microRNAs (miRNAs) are nowadays emerging as master regulators of normal physiology- and tumor-related gene expression. Thus, it is not surprising that these molecules can also regulate chemoresistance.

In this review we summarize the findings from the last decade regarding the molecular mechanisms of chemoresistance in HCC, focusing on the involvement of miRNAs. We especially highlight the role of these molecules in drug efflux through ABC (ATP-binding cassette) transporters and autophagy.

**miRNAs IN THE DEVELOPMENT OF HCC CHEMORESISTANCE**

miRNAs are short RNA molecules of 18-25 nucleotides in length. They are non-coding molecules that regulate the expression of many genes. By binding to the 3´-untranslated region (UTR) of target genes through base complementarity, miRNAs lead to mRNA degradation or translational repression, acting as negative regulators of gene expression[6]. Many reports have described a role of these molecules in the control of diverse biological processes such as development, differentiation, cell proliferation and apoptosis[7]. They can also act as oncogenes or tumor suppressors in different human cancers.

Up to date more than 2500 miRNAs have been described in humans and each of them has been reported to silence more than one gene. miRNAs take a crucial part in different processes in normal and abnormal liver development. They are involved in lipid, cholesterol and glucose metabolism, and liver differentiation (see Ref.[8] review). They take part in apoptosis, necrosis, cell cycle, proliferation, epithelial-mesenchymal transition and inflammation[9]. Further, studies derived from the comparison between normal liver and human liver cancer showed the aberrant expression of many miRNAs in cancer cells. It was interesting to find that some of them such as, miR-21, miR-221 and miR-222 are upregulated in HCC whereas miR-122, miR-199 and the let7 family members are downregulated[7], showing the complex pattern of miRNA expression in this type of cancer. Regarding the molecular mechanisms, protein kinase B (AKT), mammalian target of rapamycin (mTOR), Wingless-type MMTV integration site family (Wnt), Janus kinase/signal transducers and activators of transcription (JAK/STAT), and Mitogen-activated protein kinases (MAPK) are the main miRNA-regulated pathways during HCC tumorigenesis[10].

Thus, many miRNAs are deregulated in HCC and some of them participate in the progression of chemoresistance[11]. Nevertheless, their precise roles in the development of drug resistance in liver cancer are not fully understood. In the following sections we particularly analyze the relationship between miRNAs and ABC transporter-mediated drug resistance in HCC. Besides, we summarize the novel evidence that relates miRNAs, autophagy and chemoresistance in HCC.

**miRNAs AND ABC TRANSPORTER-MEDIATED DRUG RESISTANCE IN HCC**

The ABC transporters are cell membrane proteins that couple the hydrolysis of ATP to extrude different types of xenobiotics and metabolites against concentration gradient. Efflux transporters such as P-glycoprotein (P-gp/*ABCB1*), breast cancer resistance protein (BCRP/*ABCG2*) and multidrug resistance-associated protein 1 (MRP1/*ABCC1*), among others, limit the exposure to chemotherapeutic drugs by extruding them from cells. Consequently, these transporters are main actors in the drug resistance phenomenon. Furthermore, their overexpression in HCC cells represents a big obstacle for chemotherapy treatment and the central mechanism that contributes to drug resistance[12]. Here we summarize the recent studies describing the role of major miRNAs on ABC transporter family proteins and their impact on HCC chemoresistance.

***miR122***

This is a liver specific miRNA[13] and it participates in lipid and cholesterol metabolism and its decreased expression has detrimental effects on the liver[8]. Frequently, miR122 is downregulated in HCC tumors denoting poor prognosis and metastatic properties[14]. In human HCC cell lines (HepG2, HuH-7, Hep3B), miR122 levels were also found reduced. Interestingly, when these cells were adenovirus-transduced to overexpress miR122 they became more sensitive to DOX- and vincristine-induced death. Remarkably, miR122-overexpressing HCC cells showed reduced levels of *ABCB1* and *ABCC1* mRNA expression (Table 1). The latter was also found downregulated at the protein level[12]. These results indicate that miR122 controls sensitivity to drug-induced HCC cell death by downregulating P-gp and MRP1 expression.

***miR27a***

miR27a is involved in tumorigenesis in different types of cancers. In leukemia cells it was shown that resistance to DOX correlates with high expression of P-gp and low levels of miR27a. The upregulation of this miRNA produced greater mortality in the presence of DOX than the observed in control cells, demonstrating the role of miR27a in chemoresistance in leukemia cells[15]. On the contrary, miR27a upregulation lead to the overexpression of P-gp in ovarian cancer and cervical carcinoma cells[16].

There was no information about the relationship between the miR27a and ABC transporters in HCC until 2013. Chen *et al*[17] developed Bel-7402 HCC cells resistant to 5-Fluoroacil (5-Fu). They found that these cells overexpressed P-gp while miR27a was almost undetectable. But when cells were transfected with miR27a, the authors observed more sensitivity to 5-Fu, DOX and mitomycin, and diminished expression of P-gp[17] (Table 1). Thus, levels of miRNA27a in HCC cells are low and seem to negatively correlate with P-gp expression.

***miR503***

This molecule is downregulated in some types of cancers such as gastric and endometrial tumors, while it is overexpressed in others, like retinoblastoma or parathyroid carcinoma[18]. In HCC samples, this miRNA is downregulated with respect to non-tumor liver tissues, and this low level is related to malignant progression[19]. Furthermore, the expression of miR503 in different HCC cell lines is also decreased. Wang *et al*[20] found that miR503 was reduced in DOX-resistant HepG2 HCC cells. Besides, these cells overexpressed both P-gp and MRP1 transporters[20]. Further, HepG2 cells transfected to overexpress miR503 showed a reduction in the expression of both transporters at protein level, and at mRNA level as well (Table 1). Interestingly, cells overexpressing miR503 also showed an increased sensitivity to DOX and accumulated more intracellular rhodamine-123[20]. This fluorophore is known to be extruded from the cells through P-gp, therefore these results indicate that miR503 controls sensitivity to DOX-induced death in HepG2 cells by reducing P-gp and MRP1 expression and increasing intracellular drug concentration.

***miR375***

Initially, this molecule was identified in pancreatic cells. It regulates insulin secretion so it takes part of glucose homeostasis. In many cancers, it is downregulated and acts as a tumor suppressor[21]. In HCC, miR375 is one of the most downregulated miRNAs in tumor tissues and cell lines. Its ectopic overexpression was demonstrated to decrease liver cancer cell growth and invasion, and to promote apoptosis[21,22]. Moreover, miR-375 suppressed astrocyte elevated gene-1 (*AEG-1*) expression by binding directly to its 3′-UTR[22], and AEG-1 overexpression increased P-gp protein levels in HCC cells[23].

In a recent study, DOX-resistant HepG2 cells were established and they overexpressed P-gp. However, when miR375-containing lipid-coated nanoparticles were delivered to these cells, P-gp expression decreased under control cell levels. Also, in cell viability assays, the half inhibitory concentration (IC50) of different HCC cell lines (HepG2, HuH-7, Hep3B and HepG2 resistant to DOX) incubated with nanoparticles containing both DOX and miR375 was lower than the IC50 of cells cultured with DOX or nanoparticles containing DOX alone (Table 1). Importantly, nanoparticles loaded with miR375 suppressed liver tumor growth, enhanced the therapeutic effect of DOX and reduced drug toxicity in mice[24].

***miR133a***

This miRNA is downregulated in breast cancer cell lines and tissues, and this decrease is related to advanced clinical stages[25]. Besides, it's downregulation has been associated with metastasis and recurrence of prostate cancer[26]. In HCC cell lines and tissues, miR133a was also found downregulated and its low expression was related with poor differentiated tumors[27]. Interestingly, predictions performed with computational programs revealed that the 3’UTR of MRP1/*ABCC1* transporter gene includes a binding site for miR133a (and also for miR326). By luciferase reporter assay it was confirmed that miR133a binds to the 3’UTR of *ABCC1* gene and controls MRP1 expression. Remarkably, miR133a overexpression in HepG2 cells induced a significant decrease in MRP1 mRNA and protein levels (Table 1). Besides, in the presence of DOX, cells overexpressing miR133a were more sensitive to drug-induced death than control cells[28].

***miR326***

This miRNA was found to be downregulated in gastric cancer[29]. In breast cancer cells and tissues its expression negatively correlated with MRP1 transporter levels. Furthermore, elevated miR326 levels sensitized cells to cytotoxic drugs[30]. In human HCC tissues, this miRNA was also found downregulated and its reduced expression correlated with tumor malignancy and patient lymph node metastasis. *In vitro*, miR326 inhibited tumor cell proliferation and invasion, and promoted apoptosis *in vivo*[31]. Regarding its role as modulator of ABC transporter expression, computational programs predicted a binding site for miR326 at the 3’UTR of *ABCC1* gene. This binding site was also confirmed by luciferase reporter assay (Table 1). In addition, it was demonstrated that HCC cells overexpressing miR326 had reduced levels of MRP1, both at mRNA and protein levels. Further, miR326-overexpressing HepG2 cells showed more sensitivity to DOX than control cells[28].

***miR223***

In colon cancer, miR223 is upregulated and acts as an oncogene. On the contrary, it is frequently downregulated in leukemia and lymphomas[32]. In HCC, this miRNA is also reduced and it was shown to induce HepG2 and Bel-7402 cell growth suppression and to promote apoptosis[33]. Moreover, lower miR223 levels were found in HCC patient sera respect to healthy volunteers, and a reduced expression was also determined in liver biopsies compared with normal liver. Thus, this miRNA has been proposed as a novel potential biomarker for HCC[34].

Yang *et al*[35] showed that P-gp proteinexpression was higher in some HCC cell lines such as Hep3B, HCC3, LM-6, SMMC7721, HuH-7 and HepG2, than in others like Hep3B and BEL-7402 cells. Moreover P-gp levels positively correlated with DOX IC50. Interestingly, using bioinformatics techniques miR223 was first predicted to bind to the 3´ UTR of *ABCB1* gene. This was later confirmed by performing an EGFP reporter assay where miR223 was proved to specifically interact with the 3´ UTR of *ABCB1* gene. Further, miR223 expression was found to be differentially expressed and inversely correlated with P-gp levels when comparison was made among the eight cell lines. Besides, inhibition of miR223 expression was verified to induce P-gp expression in most of the HCC cell lines analyzed[35]. In addition, transfection of HCC cells with miR223 mimics showed the inhibition of P-gp expression (Table 1), both at mRNA and protein levels (Table 1), and an increase in cell mortality under paclitaxel and DOX treatment. These results were confirmed by upregulating P-gp expression and through a rescue experiment by overexpressing *ABCB1* lacking the 3’UTR. Therefore, this study demonstrates that miR223 has a relevant role in HCC cell chemoresistance by controlling P-gp expression[35].

***miR491-3p***

In multidrug-resistant cancer tongue cells, this miRNA was found to be decreased and the induction of its expression sensitized cells to chemotherapy[36]. Also in osteosarcoma cells and tissues, miR491-3p was observed downregulated and when its expression was restored, the suppression of tumor growth and invasion was demonstrated[37].

Recently, it was demonstrated that this miRNA is also downregulated in HCC cell lines. Furthermore, in liver tumors miR491-3p levels were reduced compared with matched non-tumor tissues. Besides, P-gp levels were higher in HCC Hep3B, BEL-7402 and SMMC-7721 cells than in normal human liver cell lines (THLE-2 and THLE-3). Notably, P-gp expression inversely correlated with miR491-3p in both tumor and normal liver cells (Table 1). This negative correlation was also found in clinical samples[38]. Moreover, using bioinformatic algorithms, different miRNAs -including miR491-3p- were predicted as candidates to bind to the 3’UTR of *ABCB1* gene. miR491-3p specific interaction with the 3’UTRs of *ABCB1* was confirmed performing luciferase reporter gene assays. Interestingly, specificity protein 3 (SP3, a transcription factor suggested to induce *ABCB1* expression) was demonstrated to be another target of miR491-3p. miR491-3p levels inversely correlated with SP3 expression in both HCC cells and liver tumors. Remarkably, Hep3B cells transfected with miR491-3p mimics were more sensitive to DOX and vinblastine. On the contrary, overexpression of P-gp or SP3 restored chemoresistance reverting the sensitivity conferred by miR491-3p. Therefore, a loop including miR491-3p, SP3 and MDR1 in HCC cell chemoresistance was proposed[38].

***miR183***

The expression of this miRNA is deregulated in some malignancies such as leukemia, breast cancer and liver tumors[39]. miR183 downregulation correlated with metastasis in lung cancer[40]; however, this mRNA was upregulated in HCC tissues as compared to the adjacent non-tumor liver zone[41]. Further, the programmed cell death 4 (*PDCD4*) tumor suppressor gene was downregulated in HCC cells transfected with miR183[41]. Wang *et al*[42] showed that miR183 was overexpressed in HCC Bel-7402/5-Fu (resistant to 5-FU) cells. P-gp and MRP2 protein expression was also increased in Bel-7402/5-Fu cells (Table 1), and the suppression of miR183 in these cells diminished P-gp and MRP2 protein levels. In addition, the authors established that high levels of miR183 induced the expression of both transporters in control cells. So, these results indicate that miR183 modulates P-gp and MRP2 expression.

Thus, a large amount of evidence points that many miRNAs are deregulated in HCC and some of them are involved in chemoresistance. Nevertheless, until the recent years the precise mechanisms underlying miRNA-induced drug resistance in this malignancy have not been fully understood. Many efforts have been targeted to decipher how aberrantly expressed miRNAs affect tumor cell proliferation or apoptosis pathways. Here, we investigated thoroughly the recent findings that reveal that certain miRNAs regulate ABC transporter expression by specifically targeting, for instance, *ABCB1* and/or *ABCC1* genes. Most of these miRNAs are found downregulated in HCC tissues and cells. As a consequence, P-gp and/or MRP1 expression levels increase and intracellular therapeutic drug accumulation decrease, making HCC cells less sensitive to death (Table 1). Altogether, these findings indicate that miRNAs have a key role in ABC transporter-mediated drug resistance in HCC.

**AUTOPHAGY IN THE DEVELOPMENT OF HCC CHEMORESISTANCE**

Autophagy is an evolutionary conserved mechanism that involves proteolytic degradation of cytosolic components at the lysosome through lysosomal enzyme action that facilitate degradation of sequestered products[43]. It occurs mainly as a response to cellular stress (infection, hypoxia, *etc*.) and its leading function is to grant nutrients for cellular functions and to remove unwanted material from the cytosol such as damaged organelles, acting as a cytoprotective system[44].

Autophagy includes five phases: initiation, elongation and autophagosome formation, fusion, and autolysosome formation. This process begins with the development of an isolated membrane, called phagophore, which origin is controversial. It expands and engulfs intracellular organelles or protein aggregates (for example) in a double-membrane vesicle called autophagosome. Then, maturation occurs when autophagosome fuses with a lysosome to form an autolysosome, promoting the degradation of the inside contents. Finally, aminoacids, fatty acids, and nucleotides are transported to the cytoplasm, so they can be re-used by the cell[43]. Thus, autophagy works as a recycling machinery that removes non-functional proteins and organelles.

The molecular pathway of autophagy has been thoroughly reviewed elsewhere[45,46]. Briefly, the initial phase is driven by the unc-51-like autophagy activating kinase (ULK) complex and the class III phosphatidylinositol 3-kinase (PtdIns3K) complex. The last complex produces phosphatidylinositol 3-phosphate for recruitment of other factors to the phagophore, and contains the key autophagy regulators vacuolar protein sorting 34 (VPS34), VPS15, Beclin 1 and activating molecule in Beclin 1-regulated autophagy (AMBRA1). Downstream, the autophagy-related gene 8 (ATG8) andATG12 systems (two ubiquitin-like conjugation systems) mediate vesicle expansion. The E1-like protein ATG7 is required for activation of ATG8 (light chain 3 (LC3) in mammals) and ATG12. ATG8/LC3 is subjected to proteolysis and then is covalently attached to the lipid phosphatidylethanolamine (in mammalian cells, the precursor form is LC3-I and LC3-II is the lipidated one), by which it associates with the phagophore membrane. Thus, autophagy can be detected biochemically (by assessing LC3-II generation) or microscopically (by observing LC3 puncta formation, indicative of LC3 redistribution to the autophagosomes under development). The pathway includes other proteins such as ATG9, factors required for autophagosome–lysosome fusion (*e.g.*, lysosomal-associated membrane protein 2), vacuolar permeases that mediate amino acid efflux from the lysosome, and lysosomal enzymes involved in cargo degradation[45,46].

In normal liver, damaged mitochondria and mutated cells are removed through autophagy, and this mechanism suppresses tumor initiation. But once the tumor is established, autophagy acts as a pro-oncogenic factor, as it promotes tumor growth metastasis and resistance to therapeutic drugs (revised in[47,48]). Actually, inhibition of autophagy in HCC cells incubated with sorafenib and bevacizumab enhanced cell lethality[49,50]. Moreover, autophagy modulation participated in oncolytic virotherapy in a liver cancer stem cell model[51]. Thus, appropriate autophagy regulation could effectively suppress HCC growth and metastasis. In this section, we describe the recent findings concerning the effect of miRNAs in autophagy and chemoresistance in HCC.

***miR26a/b***

This molecule is upregulated in some malignant cancers such as glioma and glioblastoma. On the other hand, it is downregulated in some bladder tumors, breast cancer cell lines and tissues, and anaplastic thyroid carcinoma, among others[52]. Particularly in HCC, miR26a/b is downregulated and its overexpression was shown to reduce HepG2 and MHCC97-H HCC cell proliferation, migration and invasion[53]. Thus, miR26a/b might play a suppressive role in liver tumor progression.

Jin *et al*[54] found that DOX treatment induced autophagy and reduced miR26a/b levels in HepG2 cells. Further, in DOX-resistant HepG2 cells this miRNA was also downregulated. In both cell lines, incubation with autophagy inhibitors resulted in the upregulation of miR26a/b, whereas the opposite effect was observed when an autophagy inducer was used. This implies that autophagy can modulate the expression of this miRNA[54]. Remarkably, miR26a/b overexpression in resistant cells sensitized them to apoptosis induced by DOX. Moreover, when miR-26a/b was combined with DOX treatment, miR-26a/b further improved the therapeutic effect of this drug on tumor growth *in vivo.* Besides, the authors performed bioinformatics analysis and reporter gene assays and found that ULK1 (a protein that participates in the initial stage of autophagy) is a target of miR26a/b in HCC cells (Table 2). The overexpression of miR26a/b induced the reduction not only of ULK1, but also of another proteins involved in autophagy (Beclin-1, ATG7 and LC3-II), on the contrary, downregulation of miR26a/b induced the increase of the formers. Thus, miR26 modulates autophagy (suppressing ULK1 expression) in order to promote apoptosis and sensitize HCC to chemotherapy. The authors propose that the combination of miR26a/b with chemotherapy could introduce a new strategy to overcome cancer[54].

***miR199a-5p***

In triple negative breast cancer cells this miRNA is downregulated, and suppresses cell migration and invasion[55]. On the other hand, it is upregulated in osteosarcoma cells and patient tissues and its knock-down brings about a reduction in cell proliferation and tumor growth[56]. In HCC cells and tissues, miR199a-5pis frequently downregulated and its overexpression inhibits cell proliferation, migration and invasion *in vitro* and *in vivo*[57]. Moreover, low miR199a-5p expression in HCC patients was associated with poor prognosis. Interestingly, cisplatin treatment decreased miR199a-5p levels and induced autophagy in two HCC cell lines, HuH-7 and HepG2. However, when the expression of miR199a-5p was forced, cisplatin-induced autophagy was inhibited and cisplatin-induced decrease of cell proliferation was increased. Accordingly, it was found that miR199a-5p interacts with the 3´UTR region of *ATG7* transcript (Table 2)*.* Thus, cisplatin, *via* miR199a-5p downregulation, increases drug resistance by inducing autophagy in HCC cells[58].

***miR101***

This miRNA is involved in the development and progression of oral squamous-cell cancer. In these tissues, it is downregulated and related to patient poor prognosis[59]. In non-small cell lung cancer, it is almost undetectable and this absence is related to lymph node metastasis and poor prognosis of patients[60]. Further, in HCC it was observed that patients with distant metastasis had lower levels of miR101, and the downregulation of this miRNA correlated with adverse prognosis. Besides, lentivirus-delivered miR101 avoided tumor growth and metastasis in a HCC murine model[61].

In a study performed with HepG2 HCC cells, it was shown that miR101 induced apoptosis upon cisplatin treatment. By using cells transfected with a sequence of RNA that mimics miR101 it was observed that proteins involved in the phagosome formation stathmin 1 (STMN1), RAS related protein (RAB5A), autophagy-related 4D cysteine peptidase (ATG4D) and mTOR were miR101 targets (Table 2). On the other hand, the use of a sequence of RNA that specifically binds and inhibits miR101 increased the mRNA levels of the four genes. Moreover, miR101 inhibitor induced much more phagosome formation than miR101 mimics, showing that the absence of the miRNA induces autophagy. Besides, it was also demonstrated that in the presence of cisplatin, cells with lower levels of miR101 showed less apoptosis than the ones transfected with miR101 mimics. In conclusion, miR101 inhibits autophagy and increases apoptosis induced by cisplatin in HCC cells[62].

***miR216b***

miR216b is downregulated in colorectal cancer compared with normal tissues. High expression of this miRNA inhibited cell proliferation, migration and invasion in this type of cancer through targeting the expression of the oncogene serine-arginine protein kinase 1 (SRPK1)[63]. In cervical cancer tissues and cells it is also downregulated. Its overexpression inhibited cell proliferation in cultured HeLa cells, suggesting a possible tumor suppressor activity in this type of cancer[64]. In HCC patient plasma and tissues it was also found downregulated compared with healthy volunteers and non-tumor adjacent liver tissue, respectively. Further, low expression of miR216b correlated with patient poor prognosis[65]. In HepG2 and SMMC-7721 cells, low levels of miR216b stimulated cell proliferation, migration and invasion, while its overexpression produced the opposite effect[65]. Besides, miR216b levels in BEL-7402 HCC cells inversely correlated with the expression levels ofmetastasis associated lung adenocarcinoma transcript 1 (*MALAT1*), an oncogenic long non-coding RNA (LncRNA) that is generally upregulated in this tumor and can modulate chemosensitivity[66]. By performing gene reporter assays, it was shown that miR216b has two binding sites in *MALAT1*. Both *MALAT1*-siRNA and miR216b mimics inhibited autophagy in BEL-7402/5-FU (BEL-7402 cells 5-FU resistant) cells, and autophagy inhibition significantly increased 5-FU-induced cell apoptosis (Table 2). Moreover, these treatments decreased the IC50 of 5-FU, DOX, and mitomycin in BEL-7402/5-FU cells[66]. These results revealed the relationship between autophagy, *MALAT1* and miR216b, contributing to HCC chemosensitivity.

***miR142-3p***

This miRNA is downregulated in non-small cell lung cancer (NSCLC) tissues and cell lines. At high levels, it prevents tumorigenesis inhibiting the expression of one of the high mobility group protein superfamily, HMGB1, involved in cancer cell migration and invasion[67]. Besides, this miRNA is diminished in ovarian cancer tissues and cell lines, and its downregulation is related to poor differentiation. Further, it was demonstrated that overexpression of miR142-3p inhibited proliferation and chemoresistance in ovarian cancer cells[68]. In HCC tissues it is also downregulated, and the expression levels decreased as the disease progressed. miR142-p3 overexpression inhibited BEL-7402 and SMMC-7721 HCC cell migration and invasion, thus, it was suggested to suppress metastasis[69].

Zhang *et al*[70] studied the role of miR142-3p in sorafenib resistance in SMMC-7721 and HepG2 HCC cells. They showed that cells incubated with this drug presented a higher autophagic flux than control cells in a dose- and time-dependent manner. When autophagy was inhibited, cells become sensible to the drug. They also showed that miR142-3p was downregulated in HCC cells under sorafenib treatment. Furthermore, it was shown that high levels of the miRNA negatively regulated sorafenib-induced autophagy in HCC cells by binding to the 3´-UTR of ATG5 and ATG16L1 mRNAs (both part of the autophagy machinery) (Table 2). Therefore, these data indicate that miR142-3p downregulation induces autophagy by increasing the level of ATG5 and ATG16L1, and thus promoting sorafenib resistance in HCC[70].

***miR21***

This miRNA is frequently upregulated in cancer cell lines and human tumors. It is very important in oncogenic processes as it is associated with high proliferation, reduced apoptosis, metastasis potential and invasion[71]. In HCC it is also overexpressed and it was suggested to be related to tumor progression in patients[72]. Treatment with an oligonucleotide anti-miR21 led to the loss of viability, induction of apoptosis and necrosis in different HCC cell lines. Further, anti-miR21 also diminished cell migration and suppressed clonogenic growth[73].

 He *et al*[74] developed sorafenib-resistant HuH-7 and HepG2 HCC cells and found that miR21 was upregulated. Interestingly, drug-sensitive parental cells transfected with miRNA21 mimics also became resistant. It was also demonstrated that sorafenib upregulated the expression of two key autophagic proteins (LC3-II and Beclin-1), but the expression level of both proteins in parental cells was higher than in drug-resistant ones. Besides, parental cells showed more acidic vesicular organelles than resistant cells. These results indicated that autophagy is more activated in parental cells than in the resistant ones. Interestingly, autophagy induction with rapamycin inhibited sorafenib-resistant cell growth, indicating that this process increases sensitivity to sorafenib in resistant cells[74]. Further, inhibition of miR21 by using an antisense miRNA oligonucleotide, re-sensitized resistant cells to sorafenib by promoting autophagy and stimulating apoptosis. On the other hand, miR21 mimics reduced autophagy, apoptosis, and the expression of phosphatase and tensin homologue (PTEN) protein (a known target of miR21) in parental cell lines (Table 2). Finally experiments performed with resistant cell-derived tumors established in mice showed that sorafenib administration plus intratumoral injection of anti-miR21 oligonucleotides induced a reduction in tumor size. Moreover, sorafenib administration downregulated PTEN, upregulated LC3-II and Beclin-1 expression in tumor lysates, and increased the activation of p-AKT. While anti-miR21 induced the upregulation of PTEN, LC-II and Beclin-1, and reduced expression of p-AKT[74]. Therefore, acquired sorafenib resistance might be mediated by the overexpression of miR21 and the inhibition of autophagy, probably by regulating the PTEN/AKT pathway.

***miR423-5p***

This miRNA, overexpressed in glioblastoma, was shown to enhance angiogenesis, tumor cell growth and invasion[75]. In gastric cancer, miR423-5p was also upregulated, and this overexpression favored cell cycle progression and decreased cell migration and invasion[76]. Particularly in HCC tissues it is upregulated, and high levels of this miRNA constitute a factor that increases cell invasiveness in HCC cells[77].

Interestingly, sorafenib treatment increased miR423-5p levels in conditioned media of HepG2 and HuH-7 HCC cells and in serum of patients, suggesting a potential role of miR423-5p as a marker of sorafenib response in HCC patients. Transfection of HCC cells with an anti-miRNA diminished LC-II and ATG7 protein levels (an autophagic vacuole formation protein). Accordingly, transfection with miR423-5p mimic induced vacuole and autophagosome formation (Table 2), and the opposite was observed with the miRNA inhibitor. In conclusion, it was suggested that this miRNA has a biological role in autophagy in HCC and it was proposed as a helpful tool to predict patient response to sorafenib treatment[78].

Thus, most miRNAs described here target the expression of autophagy-related genes, inhibiting autophagy and acting as tumor suppressors. However, in HCC tissues and cells many of these miRNAs are downregulated, or their levels are reduced after therapeutic drug treatment. As a consequence of this downregulation, miRNAs do not inhibit autophagy and tumor growth and resistance is favored (Table 2).

**CONCLUSION**

miRNAs are deregulated in HCC cells and tissues, and they play crucial roles in the development of chemoresistance. Emerging studies point that the modulation of ABC transporter and/or autophagy-related gene expression could be determinant for HCC cell survival under chemotherapeutic drug treatment. Our knowledge about the precise mechanisms regarding miRNA involvement in resistance will lead us to find new ways of making HCC treatment more effective. The development of miRNAs, miRNAs mimics or anti-miRNA with long half lives and their use in combination with chemotherapeutic drugs could be a powerful option. Even so, there are still difficulties to overcome prior the possibility of being able to use miRNAs in clinical trials, for instance, the right delivery system. Nowadays, much research is being conducted on the use of nanoparticles to get over this trouble. Undoubtedly, more insights on the biological processes, signaling pathways and/or molecular mechanisms regulated by miRNAs are needed. Anyway, miRNA-based therapy together with conventional chemotherapeutic drugs has a great future in cancer therapy.

**REFERENCES**

1 **McGlynn KA**, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. *Clin Liver Dis* 2015; **19**: 223-238 [PMID: 25921660 DOI: 10.1016/j.cld.2015.01.001]

2 **Lohitesh K**, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. *Cancer Cell Int* 2018; **18**: 44 [PMID: 29568237 DOI: 10.1186/s12935-018-0538-7]

3 **Dimitroulis D**, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, Athanasiou A, Moris D, Sakellariou S, Kykalos S, Tsourouflis G, Garmpi A, Delladetsima I, Kontzoglou K, Kouraklis G. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. *World J Gastroenterol* 2017; **23**: 5282-5294 [PMID: 28839428 DOI: 10.3748/wjg.v23.i29.5282]

4 **Kudo M**. Systemic Therapy for Hepatocellular Carcinoma: 2017 Update. *Oncology* 2017; **93 Suppl 1**: 135-146 [PMID: 29258077 DOI: 10.1159/000481244]

5 **Cox J**, Weinman S. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. *Hepat Oncol* 2016; **3**: 57-59 [PMID: 26998221 DOI: 10.2217/hep.15.41]

6 **Oliveto S**, Mancino M, Manfrini N, Biffo S. Role of microRNAs in translation regulation and cancer. *World J Biol Chem* 2017; **8**: 45-56 [PMID: 28289518 DOI: 10.4331/wjbc.v8.i1.45]

7 **Gailhouste L**, Gomez-Santos L, Ochiya T. Potential applications of miRNAs as diagnostic and prognostic markers in liver cancer. *Front Biosci (Landmark Ed)* 2013; **18**: 199-223 [PMID: 23276918 DOI: 10.2741/4096]

8 **Szabo G**, Bala S. MicroRNAs in liver disease. *Nat Rev Gastroenterol Hepatol* 2013; **10**: 542-552 [PMID: 23689081 DOI: 10.1038/nrgastro.2013.87]

9 **Mizuguchi Y**, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. *Hepatol Res* 2016; **46**: 391-406 [PMID: 26490438 DOI: 10.1111/hepr.12606]

10 **Vasuri F**, Visani M, Acquaviva G, Brand T, Fiorentino M, Pession A, Tallini G, D'Errico A, de Biase D. Role of microRNAs in the main molecular pathways of hepatocellular carcinoma. *World J Gastroenterol* 2018; **24**: 2647-2660 [PMID: 29991871 DOI: 10.3748/wjg.v24.i25.2647]

11 **Corrà F**, Agnoletto C, Minotti L, Baldassari F, Volinia S. The Network of Non-coding RNAs in Cancer Drug Resistance. *Front Oncol* 2018; **8**: 327 [PMID: 30211115 DOI: 10.3389/fonc.2018.00327]

12 **Xu Y**, Xia F, Ma L, Shan J, Shen J, Yang Z, Liu J, Cui Y, Bian X, Bie P, Qian C. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. *Cancer Lett* 2011; **310**: 160-169 [PMID: 21802841 DOI: 10.1016/j.canlet.2011.06.027]

13 **Jopling C**. Liver-specific microRNA-122: Biogenesis and function. *RNA Biol* 2012; **9**: 137-142 [PMID: 22258222 DOI: 10.4161/rna.18827]

14 **Coulouarn C**, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. *Oncogene* 2009; **28**: 3526-3536 [PMID: 19617899 DOI: 10.1038/onc.2009.211]

15 **Feng DD**, Zhang H, Zhang P, Zheng YS, Zhang XJ, Han BW, Luo XQ, Xu L, Zhou H, Qu LH, Chen YQ. Down-regulated miR-331-5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia. *J Cell Mol Med* 2011; **15**: 2164-2175 [PMID: 21070600 DOI: 10.1111/j.1582-4934.2010.01213.x]

16 **Zhu H**, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, Yang JM. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. *Biochem Pharmacol* 2008; **76**: 582-588 [PMID: 18619946 DOI: 10.1016/j.bcp.2008.06.007]

17 **Chen Z**, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu T, Li J. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. *Cell Signal* 2013; **25**: 2693-2701 [PMID: 24018051 DOI: 10.1016/j.cellsig.2013.08.032]

18 **Noguchi T**, Toiyama Y, Kitajima T, Imaoka H, Hiro J, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Toden S, Kusunoki M. miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer. *Oncology* 2016; **90**: 221-231 [PMID: 26999740 DOI: 10.1159/000444493]

19 **Xiao Y**, Tian Q, He J, Huang M, Yang C, Gong L. MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor. *Onco Targets Ther* 2016; **9**: 3535-3544 [PMID: 27366090 DOI: 10.2147/OTT.S106351]

20 **Wang D**, Zhang N, Ye Y, Qian J, Zhu Y, Wang C. Role and mechanisms of microRNA‑503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. *Mol Med Rep* 2014; **10**: 3268-3274 [PMID: 25269574 DOI: 10.3892/mmr.2014.2591]

21 **Yan JW**, Lin JS, He XX. The emerging role of miR-375 in cancer. *Int J Cancer* 2014; **135**: 1011-1018 [PMID: 24166096 DOI: 10.1002/ijc.28563]

22 **He XX**, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH, Lin JS. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. *Oncogene* 2012; **31**: 3357-3369 [PMID: 22056881 DOI: 10.1038/onc.2011.500]

23 **Yoo BK**, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB, Sarkar D. Molecular mechanism of chemoresistance by astrocyte elevated gene-1. *Cancer Res* 2010; **70**: 3249-3258 [PMID: 20388796 DOI: 10.1158/0008-5472.CAN-09-4009]

24 **Xue H**, Yu Z, Liu Y, Yuan W, Yang T, You J, He X, Lee RJ, Li L, Xu C. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma. *Int J Nanomedicine* 2017; **12**: 5271-5287 [PMID: 28769563 DOI: 10.2147/IJN.S135306]

25 **Sui Y**, Zhang X, Yang H, Wei W, Wang M. MicroRNA-133a acts as a tumour suppressor in breast cancer through targeting LASP1. *Oncol Rep* 2018; **39**: 473-482 [PMID: 29207145 DOI: 10.3892/or.2017.6114]

26 **Tang Y**, Pan J, Huang S, Peng X, Zou X, Luo Y, Ren D, Zhang X, Li R, He P, Wa Q. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling. *J Exp Clin Cancer Res* 2018; **37**: 160 [PMID: 30021600 DOI: 10.1186/s13046-018-0813-4]

27 **Zhang W**, Liu K, Liu S, Ji B, Wang Y, Liu Y. MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma. *Tumour Biol* 2015; **36**: 9779-9788 [PMID: 26156803 DOI: 10.1007/s13277-015-3749-8]

28 **Ma J**, Wang T, Guo R, Yang X, Yin J, Yu J, Xiang Q, Pan X, Tang H, Lei X. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. *J Drug Target* 2015; **23**: 519-524 [PMID: 25714665 DOI: 10.3109/1061186X.2015.1015536]

29 **Ji S**, Zhang B, Kong Y, Ma F, Hua Y. miR-326 Inhibits Gastric Cancer Cell Growth Through Downregulating NOB1. *Oncol Res* 2017; **25**: 853-861 [PMID: 27733214 DOI: 10.3727/096504016X14759582767486]

30 **Liang Z**, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, Shim H. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. *Biochem Pharmacol* 2010; **79**: 817-824 [PMID: 19883630 DOI: 10.1016/j.bcp.2009.10.017]

31 **Hu S**, Ran Y, Chen W, Zhang Y, Xu Y. MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1. *Oncol Rep* 2017; **38**: 1569-1578 [PMID: 28713953 DOI: 10.3892/or.2017.5810]

32 **Liu L**, Zhang C, Li X, Sun W, Qin S, Qin L, Wang X. miR-223 promotes colon cancer by directly targeting p120 catenin. *Oncotarget* 2017; **8**: 63764-63779 [PMID: 28969027 DOI: 10.18632/oncotarget.19541]

33 **Dong Z**, Qi R, Guo X, Zhao X, Li Y, Zeng Z, Bai W, Chang X, Hao L, Chen Y, Lou M, Li Z, Lu Y. MiR-223 modulates hepatocellular carcinoma cell proliferation through promoting apoptosis via the Rab1-mediated mTOR activation. *Biochem Biophys Res Commun* 2017; **483**: 630-637 [PMID: 27998765 DOI: 10.1016/j.bbrc.2016.12.091]

34 **Bhattacharya S**, Steele R, Shrivastava S, Chakraborty S, Di Bisceglie AM, Ray RB. Serum miR-30e and miR-223 as Novel Noninvasive Biomarkers for Hepatocellular Carcinoma. *Am J Pathol* 2016; **186**: 242-247 [PMID: 26776075 DOI: 10.1016/j.ajpath.2015.10.003]

35 **Yang T**, Zheng ZM, Li XN, Li ZF, Wang Y, Geng YF, Bai L, Zhang XB. MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells. *Exp Biol Med (Maywood)* 2013; **238**: 1024-1032 [PMID: 23925649 DOI: 10.1177/1535370213497321]

36 **Zheng G**, Jia X, Peng C, Deng Y, Yin J, Zhang Z, Li N, Deng M, Liu X, Liu H, Lu M, Wang C, Gu Y, He Z. The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer. *Oncotarget* 2015; **6**: 6931-6943 [PMID: 25749387 DOI: 10.18632/oncotarget.3165]

37 **Duan J**, Liu J, Liu Y, Huang B, Rao L. miR-491-3p suppresses the growth and invasion of osteosarcoma cells by targeting TSPAN1. *Mol Med Rep* 2017; **16**: 5568-5574 [PMID: 28849017 DOI: 10.3892/mmr.2017.7256]

38 **Zhao Y**, Qi X, Chen J, Wei W, Yu C, Yan H, Pu M, Li Y, Miao L, Li C, Ren J. The miR-491-3p/Sp3/ABCB1 axis attenuates multidrug resistance of hepatocellular carcinoma. *Cancer Lett* 2017; **408**: 102-111 [PMID: 28844709 DOI: 10.1016/j.canlet.2017.08.027]

39 **Lowery AJ**, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. *BMC Cancer* 2010; **10**: 502 [PMID: 20858276 DOI: 10.1186/1471-2407-10-502]

40 **Wang G**, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. *FEBS Lett* 2008; **582**: 3663-3668 [PMID: 18840437 DOI: 10.1016/j.febslet.2008.09.051]

41 **Li J**, Fu H, Xu C, Tie Y, Xing R, Zhu J, Qin Y, Sun Z, Zheng X. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. *BMC Cancer* 2010; **10**: 354 [PMID: 20602797 DOI: 10.1186/1471-2407-10-354]

42 **Wang XJ**, Zhang DL, Fu C, Wei BZ, Li GJ. MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1α feedback loop. *Eur Rev Med Pharmacol Sci* 2016; **20**: 2020-2027 [PMID: 27249600]

43 **Glick D**, Barth S, Macleod KF. Autophagy: cellular and molecular mechanisms. *J Pathol* 2010; **221**: 3-12 [PMID: 20225336 DOI: 10.1002/path.2697]

44 **Dikic I**, Elazar Z. Mechanism and medical implications of mammalian autophagy. *Nat Rev Mol Cell Biol* 2018; **19**: 349-364 [PMID: 29618831 DOI: 10.1038/s41580-018-0003-4]

45 **Abada A**, Elazar Z. Getting ready for building: signaling and autophagosome biogenesis. *EMBO Rep* 2014; **15**: 839-852 [PMID: 25027988 DOI: 10.15252/embr.201439076]

46 **Klionsky DJ**, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC Jr, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, Ghosh P, Giammarioli AM, Giatromanolaki AN, Gibson SB, Gilkerson RW, Ginger ML, Ginsberg HN, Golab J, Goligorsky MS, Golstein P, Gomez-Manzano C, Goncu E, Gongora C, Gonzalez CD, Gonzalez R, González-Estévez C, González-Polo RA, Gonzalez-Rey E, Gorbunov NV, Gorski S, Goruppi S, Gottlieb RA, Gozuacik D, Granato GE, Grant GD, Green KN, Gregorc A, Gros F, Grose C, Grunt TW, Gual P, Guan JL, Guan KL, Guichard SM, Gukovskaya AS, Gukovsky I, Gunst J, Gustafsson AB, Halayko AJ, Hale AN, Halonen SK, Hamasaki M, Han F, Han T, Hancock MK, Hansen M, Harada H, Harada M, Hardt SE, Harper JW, Harris AL, Harris J, Harris SD, Hashimoto M, Haspel JA, Hayashi S, Hazelhurst LA, He C, He YW, Hébert MJ, Heidenreich KA, Helfrich MH, Helgason GV, Henske EP, Herman B, Herman PK, Hetz C, Hilfiker S, Hill JA, Hocking LJ, Hofman P, Hofmann TG, Höhfeld J, Holyoake TL, Hong MH, Hood DA, Hotamisligil GS, Houwerzijl EJ, Høyer-Hansen M, Hu B, Hu CA, Hu HM, Hua Y, Huang C, Huang J, Huang S, Huang WP, Huber TB, Huh WK, Hung TH, Hupp TR, Hur GM, Hurley JB, Hussain SN, Hussey PJ, Hwang JJ, Hwang S, Ichihara A, Ilkhanizadeh S, Inoki K, Into T, Iovane V, Iovanna JL, Ip NY, Isaka Y, Ishida H, Isidoro C, Isobe K, Iwasaki A, Izquierdo M, Izumi Y, Jaakkola PM, Jäättelä M, Jackson GR, Jackson WT, Janji B, Jendrach M, Jeon JH, Jeung EB, Jiang H, Jiang H, Jiang JX, Jiang M, Jiang Q, Jiang X, Jiang X, Jiménez A, Jin M, Jin S, Joe CO, Johansen T, Johnson DE, Johnson GV, Jones NL, Joseph B, Joseph SK, Joubert AM, Juhász G, Juillerat-Jeanneret L, Jung CH, Jung YK, Kaarniranta K, Kaasik A, Kabuta T, Kadowaki M, Kagedal K, Kamada Y, Kaminskyy VO, Kampinga HH, Kanamori H, Kang C, Kang KB, Kang KI, Kang R, Kang YA, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar A, Kerkhoff C, Kessel DH, Khalil H, Kiel JA, Kiger AA, Kihara A, Kim DR, Kim DH, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, Kitamoto K, Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BC, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Kouri Flores JB, Kovács AL, Kraft C, Krainc D, Krämer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Krüger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, La Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, László L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, Le W, Le Cam L, Ledbetter DJ, Lee AJ, Lee BW, Lee GM, Lee J, Lee JH, Lee M, Lee MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, Lonial S, Loos B, Lopez-Berestein G, López-Otín C, Lossi L, Lotze MT, Lőw P, Lu B, Lu B, Lu B, Lu Z, Luciano F, Lukacs NW, Lund AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MC, Malorni W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Mariño G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin B, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, Meisler MH, Meléndez A, Melia TJ, Melino G, Mena MA, Menendez JA, Menna-Barreto RF, Menon MB, Menzies FM, Mercer CA, Merighi A, Merry DE, Meschini S, Meyer CG, Meyer TF, Miao CY, Miao JY, Michels PA, Michiels C, Mijaljica D, Milojkovic A, Minucci S, Miracco C, Miranti CK, Mitroulis I, Miyazawa K, Mizushima N, Mograbi B, Mohseni S, Molero X, Mollereau B, Mollinedo F, Momoi T, Monastyrska I, Monick MM, Monteiro MJ, Moore MN, Mora R, Moreau K, Moreira PI, Moriyasu Y, Moscat J, Mostowy S, Mottram JC, Motyl T, Moussa CE, Müller S, Muller S, Münger K, Münz C, Murphy LO, Murphy ME, Musarò A, Mysorekar I, Nagata E, Nagata K, Nahimana A, Nair U, Nakagawa T, Nakahira K, Nakano H, Nakatogawa H, Nanjundan M, Naqvi NI, Narendra DP, Narita M, Navarro M, Nawrocki ST, Nazarko TY, Nemchenko A, Netea MG, Neufeld TP, Ney PA, Nezis IP, Nguyen HP, Nie D, Nishino I, Nislow C, Nixon RA, Noda T, Noegel AA, Nogalska A, Noguchi S, Notterpek L, Novak I, Nozaki T, Nukina N, Nürnberger T, Nyfeler B, Obara K, Oberley TD, Oddo S, Ogawa M, Ohashi T, Okamoto K, Oleinick NL, Oliver FJ, Olsen LJ, Olsson S, Opota O, Osborne TF, Ostrander GK, Otsu K, Ou JH, Ouimet M, Overholtzer M, Ozpolat B, Paganetti P, Pagnini U, Pallet N, Palmer GE, Palumbo C, Pan T, Panaretakis T, Pandey UB, Papackova Z, Papassideri I, Paris I, Park J, Park OK, Parys JB, Parzych KR, Patschan S, Patterson C, Pattingre S, Pawelek JM, Peng J, Perlmutter DH, Perrotta I, Perry G, Pervaiz S, Peter M, Peters GJ, Petersen M, Petrovski G, Phang JM, Piacentini M, Pierre P, Pierrefite-Carle V, Pierron G, Pinkas-Kramarski R, Piras A, Piri N, Platanias LC, Pöggeler S, Poirot M, Poletti A, Poüs C, Pozuelo-Rubio M, Prætorius-Ibba M, Prasad A, Prescott M, Priault M, Produit-Zengaffinen N, Progulske-Fox A, Proikas-Cezanne T, Przedborski S, Przyklenk K, Puertollano R, Puyal J, Qian SB, Qin L, Qin ZH, Quaggin SE, Raben N, Rabinowich H, Rabkin SW, Rahman I, Rami A, Ramm G, Randall G, Randow F, Rao VA, Rathmell JC, Ravikumar B, Ray SK, Reed BH, Reed JC, Reggiori F, Régnier-Vigouroux A, Reichert AS, Reiners JJ Jr, Reiter RJ, Ren J, Revuelta JL, Rhodes CJ, Ritis K, Rizzo E, Robbins J, Roberge M, Roca H, Roccheri MC, Rocchi S, Rodemann HP, Rodríguez de Córdoba S, Rohrer B, Roninson IB, Rosen K, Rost-Roszkowska MM, Rouis M, Rouschop KM, Rovetta F, Rubin BP, Rubinsztein DC, Ruckdeschel K, Rucker EB 3rd, Rudich A, Rudolf E, Ruiz-Opazo N, Russo R, Rusten TE, Ryan KM, Ryter SW, Sabatini DM, Sadoshima J, Saha T, Saitoh T, Sakagami H, Sakai Y, Salekdeh GH, Salomoni P, Salvaterra PM, Salvesen G, Salvioli R, Sanchez AM, Sánchez-Alcázar JA, Sánchez-Prieto R, Sandri M, Sankar U, Sansanwal P, Santambrogio L, Saran S, Sarkar S, Sarwal M, Sasakawa C, Sasnauskiene A, Sass M, Sato K, Sato M, Schapira AH, Scharl M, Schätzl HM, Scheper W, Schiaffino S, Schneider C, Schneider ME, Schneider-Stock R, Schoenlein PV, Schorderet DF, Schüller C, Schwartz GK, Scorrano L, Sealy L, Seglen PO, Segura-Aguilar J, Seiliez I, Seleverstov O, Sell C, Seo JB, Separovic D, Setaluri V, Setoguchi T, Settembre C, Shacka JJ, Shanmugam M, Shapiro IM, Shaulian E, Shaw RJ, Shelhamer JH, Shen HM, Shen WC, Sheng ZH, Shi Y, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shintani T, Shirihai OS, Shore GC, Sibirny AA, Sidhu SB, Sikorska B, Silva-Zacarin EC, Simmons A, Simon AK, Simon HU, Simone C, Simonsen A, Sinclair DA, Singh R, Sinha D, Sinicrope FA, Sirko A, Siu PM, Sivridis E, Skop V, Skulachev VP, Slack RS, Smaili SS, Smith DR, Soengas MS, Soldati T, Song X, Sood AK, Soong TW, Sotgia F, Spector SA, Spies CD, Springer W, Srinivasula SM, Stefanis L, Steffan JS, Stendel R, Stenmark H, Stephanou A, Stern ST, Sternberg C, Stork B, Strålfors P, Subauste CS, Sui X, Sulzer D, Sun J, Sun SY, Sun ZJ, Sung JJ, Suzuki K, Suzuki T, Swanson MS, Swanton C, Sweeney ST, Sy LK, Szabadkai G, Tabas I, Taegtmeyer H, Tafani M, Takács-Vellai K, Takano Y, Takegawa K, Takemura G, Takeshita F, Talbot NJ, Tan KS, Tanaka K, Tanaka K, Tang D, Tang D, Tanida I, Tannous BA, Tavernarakis N, Taylor GS, Taylor GA, Taylor JP, Terada LS, Terman A, Tettamanti G, Thevissen K, Thompson CB, Thorburn A, Thumm M, Tian F, Tian Y, Tocchini-Valentini G, Tolkovsky AM, Tomino Y, Tönges L, Tooze SA, Tournier C, Tower J, Towns R, Trajkovic V, Travassos LH, Tsai TF, Tschan MP, Tsubata T, Tsung A, Turk B, Turner LS, Tyagi SC, Uchiyama Y, Ueno T, Umekawa M, Umemiya-Shirafuji R, Unni VK, Vaccaro MI, Valente EM, Van den Berghe G, van der Klei IJ, van Doorn W, van Dyk LF, van Egmond M, van Grunsven LA, Vandenabeele P, Vandenberghe WP, Vanhorebeek I, Vaquero EC, Velasco G, Vellai T, Vicencio JM, Vierstra RD, Vila M, Vindis C, Viola G, Viscomi MT, Voitsekhovskaja OV, von Haefen C, Votruba M, Wada K, Wade-Martins R, Walker CL, Walsh CM, Walter J, Wan XB, Wang A, Wang C, Wang D, Wang F, Wang F, Wang G, Wang H, Wang HG, Wang HD, Wang J, Wang K, Wang M, Wang RC, Wang X, Wang X, Wang YJ, Wang Y, Wang Z, Wang ZC, Wang Z, Wansink DG, Ward DM, Watada H, Waters SL, Webster P, Wei L, Weihl CC, Weiss WA, Welford SM, Wen LP, Whitehouse CA, Whitton JL, Whitworth AJ, Wileman T, Wiley JW, Wilkinson S, Willbold D, Williams RL, Williamson PR, Wouters BG, Wu C, Wu DC, Wu WK, Wyttenbach A, Xavier RJ, Xi Z, Xia P, Xiao G, Xie Z, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamamoto A, Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, Youle RJ, Younes A, Yu L, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zacarin E, Zacks D, Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ 3rd, Zeitlin SO, Zhang H, Zhang HL, Zhang J, Zhang JP, Zhang L, Zhang L, Zhang MY, Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, Zoladek T, Zong WX, Zorzano A, Zschocke J, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 2012; **8**: 445-544 [PMID: 22966490]

47 **Liu L**, Liao JZ, He XX, Li PY. The role of autophagy in hepatocellular carcinoma: friend or foe. *Oncotarget* 2017; **8**: 57707-57722 [PMID: 28915706 DOI: 10.18632/oncotarget.17202]

48 **Huang F**, Wang BR, Wang YG. Role of autophagy in tumorigenesis, metastasis, targeted therapy and drug resistance of hepatocellular carcinoma. *World J Gastroenterol* 2018; **24**: 4643-4651 [PMID: 30416312 DOI: 10.3748/wjg.v24.i41.4643]

49 **Shi YH**, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, Wang XY, Dai Z, Peng YF, Gu CY, Qiu SJ, Fan J. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. *Autophagy* 2011; **7**: 1159-1172 [PMID: 21691147 DOI: 10.4161/auto.7.10.16818]

50 **Guo XL**, Li D, Sun K, Wang J, Liu Y, Song JR, Zhao QD, Zhang SS, Deng WJ, Zhao X, Wu MC, Wei LX. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma. *J Mol Med* (Berl) 2013; **91**: 473-483 [PMID: 23052483 DOI: 10.1007/s00109-012-0966-0]

51 **Zhang J**, Lai W, Li Q, Yu Y, Jin J, Guo W, Zhou X, Liu X, Wang Y. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models. *Biochem Biophys Res Commun* 2017; **491**: 469-477 [PMID: 28698142 DOI: 10.1016/j.bbrc.2017.07.041]

52 **Gao J**, Liu QG. The role of miR-26 in tumors and normal tissues (Review). *Oncol Lett* 2011; **2**: 1019-1023 [PMID: 22848262 DOI: 10.3892/ol.2011.413]

53 **Li Y**, Ren M, Zhao Y, Lu X, Wang M, Hu J, Lu G, He S. MicroRNA-26a inhibits proliferation and metastasis of human hepatocellular carcinoma by regulating DNMT3B-MEG3 axis. *Oncol Rep* 2017; **37**: 3527-3535 [PMID: 28440439 DOI: 10.3892/or.2017.5579]

54 **Jin F**, Wang Y, Li M, Zhu Y, Liang H, Wang C, Wang F, Zhang CY, Zen K, Li L. MiR-26 enhances chemosensitivity and promotes apoptosis of hepatocellular carcinoma cells through inhibiting autophagy. *Cell Death Dis* 2017; **8**: e2540 [PMID: 28079894 DOI: 10.1038/cddis.2016.461]

55 **Chen J**, Shin VY, Siu MT, Ho JC, Cheuk I, Kwong A. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer. *BMC Cancer* 2016; **16**: 887 [PMID: 27842518 DOI: 10.1186/s12885-016-2916-7]

56 **Wang C**, Ba X, Guo Y, Sun D, Jiang H, Li W, Huang Z, Zhou G, Wu S, Zhang J, Chen J. MicroRNA-199a-5p promotes tumour growth by dual-targeting PIAS3 and p27 in human osteosarcoma. *Sci Rep* 2017; **7**: 41456 [PMID: 28120918 DOI: 10.1038/srep41456]

57 **Zhan Y**, Zheng N, Teng F, Bao L, Liu F, Zhang M, Guo M, Guo W, Ding G, Wang Q. MiR-199a/b-5p inhibits hepatocellular carcinoma progression by post-transcriptionally suppressing ROCK1. *Oncotarget* 2017; **8**: 67169-67180 [PMID: 28978024 DOI: 10.18632/oncotarget.18052]

58 **Xu N**, Zhang J, Shen C, Luo Y, Xia L, Xue F, Xia Q. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. *Biochem Biophys Res Commun* 2012; **423**: 826-831 [PMID: 22713463 DOI: 10.1016/j.bbrc.2012.06.048]

59 **Wu B**, Lei D, Wang L, Yang X, Jia S, Yang Z, Shan C, Yang X, Zhang C, Lu B. MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1. *Am J Cancer Res* 2016; **6**: 1396-1407 [PMID: 27429852]

60 **Han L**, Chen W, Xia Y, Song Y, Zhao Z, Cheng H, Jiang T. MiR-101 inhibits the proliferation and metastasis of lung cancer by targeting zinc finger E-box binding homeobox 1. *Am J Transl Res* 2018; **10**: 1172-1183 [PMID: 29736210]

61 **Zheng F**, Liao YJ, Cai MY, Liu TH, Chen SP, Wu PH, Wu L, Bian XW, Guan XY, Zeng YX, Yuan YF, Kung HF, Xie D. Systemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targets. *PLoS Genet* 2015; **11**: e1004873 [PMID: 25693145 DOI: 10.1371/journal.pgen.1004873]

62 **Xu Y**, An Y, Wang Y, Zhang C, Zhang H, Huang C, Jiang H, Wang X, Li X. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. *Oncol Rep* 2013; **29**: 2019-2024 [PMID: 23483142 DOI: 10.3892/or.2013.2338]

63 **Yao Y**, Li Q, Wang H. MiR-216b suppresses colorectal cancer proliferation, migration, and invasion by targeting SRPK1. *Onco Targets Ther* 2018; **11**: 1671-1681 [PMID: 29615842 DOI: 10.2147/OTT.S161835]

64 **He S**, Liao B, Deng Y, Su C, Tuo J, Liu J, Yao S, Xu L. MiR-216b inhibits cell proliferation by targeting FOXM1 in cervical cancer cells and is associated with better prognosis. *BMC Cancer* 2017; **17**: 673 [PMID: 28978307 DOI: 10.1186/s12885-017-3650-5]

65 **Liu FY**, Zhou SJ, Deng YL, Zhang ZY, Zhang EL, Wu ZB, Huang ZY, Chen XP. MiR-216b is involved in pathogenesis and progression of hepatocellular carcinoma through HBx-miR-216b-IGF2BP2 signaling pathway. *Cell Death Dis* 2015; **6**: e1670 [PMID: 25741595 DOI: 10.1038/cddis.2015.46]

66 **Yuan P**, Cao W, Zang Q, Li G, Guo X, Fan J. The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy. *Biochem Biophys Res Commun* 2016; **478**: 1067-1073 [PMID: 27524242 DOI: 10.1016/j.bbrc.2016.08.065]

67 **Xiao P**, Liu WL. MiR-142-3p functions as a potential tumor suppressor directly targeting HMGB1 in non-small-cell lung carcinoma. *Int J Clin Exp Pathol* 2015; **8**: 10800-10807 [PMID: 26617792]

68 **Gao J**, Wu N, Liu X, Xia Y, Chen Y, Li S, Deng Z. MicroRNA-142-3p inhibits cell proliferation and chemoresistance in ovarian cancer via targeting sirtuin 1. *Exp Ther Med* 2018; **15**: 5205-5214 [PMID: 29904404 DOI: 10.3892/etm.2018.6107]

69 **Tsang FH**, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO, Wong CM. MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. *Front Med* 2015; **9**: 331-343 [PMID: 26293610 DOI: 10.1007/s11684-015-0409-8]

70 **Zhang K**, Chen J, Zhou H, Chen Y, Zhi Y, Zhang B, Chen L, Chu X, Wang R, Zhang C. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. *Cell Death Dis* 2018; **9**: 312 [PMID: 29472524 DOI: 10.1038/s41419-018-0344-0]

71 **Pfeffer SR**, Yang CH, Pfeffer LM. The Role of miR-21 in Cancer. *Drug Dev Res* 2015; **76**: 270-277 [PMID: 26082192 DOI: 10.1002/ddr.21257]

72 **Huang CS**, Yu W, Cui H, Wang YJ, Zhang L, Han F, Huang T. Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. *Int J Clin Exp Pathol* 2015; **8**: 7234-7238 [PMID: 26261620]

73 **Wagenaar TR**, Zabludoff S, Ahn SM, Allerson C, Arlt H, Baffa R, Cao H, Davis S, Garcia-Echeverria C, Gaur R, Huang SM, Jiang L, Kim D, Metz-Weidmann C, Pavlicek A, Pollard J, Reeves J, Rocnik JL, Scheidler S, Shi C, Sun F, Tolstykh T, Weber W, Winter C, Yu E, Yu Q, Zheng G, Wiederschain D. Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation. *Mol Cancer Res* 2015; **13**: 1009-1021 [PMID: 25758165 DOI: 10.1158/1541-7786.MCR-14-0703]

74 **He C**, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. *Oncotarget* 2015; **6**: 28867-28881 [PMID: 26311740 DOI: 10.18632/oncotarget.4814]

75 **Li S**, Zeng A, Hu Q, Yan W, Liu Y, You Y. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. *Neuro Oncol* 2017; **19**: 55-65 [PMID: 27471108 DOI: 10.1093/neuonc/now129]

76 **Liu J**, Wang X, Yang X, Liu Y, Shi Y, Ren J, Guleng B. miRNA423-5p regulates cell proliferation and invasion by targeting trefoil factor 1 in gastric cancer cells. *Cancer Lett* 2014; **347**: 98-104 [PMID: 24486742 DOI: 10.1016/j.canlet.2014.01.024]

77 **Sun X**, Wang M, Liu H, Wang J. MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1. *Am J Transl Res* 2017; **9**: 5576-5584 [PMID: 29312509]

78 **Stiuso P**, Potenza N, Lombardi A, Ferrandino I, Monaco A, Zappavigna S, Vanacore D, Mosca N, Castiello F, Porto S, Addeo R, Prete SD, De Vita F, Russo A, Caraglia M. MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib. *Mol Ther Nucleic Acids* 2015; **4**: e233 [PMID: 25782064 DOI: 10.1038/mtna.2015.8]

**P-Reviewer:** Wang YG, Yao DY **S-Editor:** Ma YJ **L-Editor:** A **E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and Hepatology

**Country of origin:** Argentina

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 miRNAs and ABC transporter-mediated drug resistance in hepatocellular carcinoma cells**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **miRNA** | **Expression Level in HCC** | **Role in ABC transporter expression and/or function** | **Involvement in cell viability and/or drug resistance** | **Ref.** |
| miR122 | Downregulated in tumors (reduced levels correlate with patient poor prognosis and metastasis) and in human HepG2, HuH-7 and Hep3B HCC cell lines | miR122-overexpressing HCC cells treated with DOX and vincristine showed reduced levels of P-gp mRNA expression, and MRP1 mRNA and protein levels | Adenovirus-transduced cells to overexpress miR122 became more sensitive to DOX- and vincristine-induced death | [12][14] |
| miR27a | Low in drug-resistant Bel-7402 cells | Negatively correlated with P-gp levels.Upregulation of miR27a reduced P-gp mRNA and protein expression | Cells transfected to overexpress miR27a sensitized resistant cells to 5-FU, mitomycin and DOX | [17] |
| miR503 | Downregulated in HCC tissues (reduced levels correlate with malignant tumor progression), in HCC cell lines (SMMC-7721, Hep3B, HepG2, MHCC97H and LM3) and HepG2 resistant to drugs | Cells transfected to overexpress miR503 showed downregulation of both P-gp and MRP1, at mRNA and protein levels, and accumulated more intracellular rhodamine-123 (extruded through P-gp) | miR503 overexpression restored sensitivity to DOX in HepG2 resistant cells | [20][19] |
| miR375 | Downregulated in patient tumor tissues and cells lines (HepG2, HuH-7, Hep3B) | Delivered within nanoparticles decreased P-gp protein expression | Delivered within nanoparticles improved DOX antitumor effect, prevented tumor cell growth *in vitro* and *in vivo* | [21][22][24] |
| miR133a | Downregulated in patient tumor tissues (its low expression correlated with poor differentiated tumors) and in HepG2, SMMC-77231, Hep3B, HuH-7 HCC cells | Through its binding to the 3´UTR of *ABCC1* gene specifically downregulated MRP1 expression | miR133a-overexpressing HepG2 cells were more sensitive to DOX-induced death | [27][28] |
|
| miR326 | Downregulated in human tissues (its low expression correlated with tumor progression and lymph node metastasis) and in HepG2, SMMC-77231, Hep3B, HuH-7 HCC cells | Specifically targeted MRP1 expression through its binding to the 3´UTR of *ABCC1* gene  | miR326-overexpressing HepG2 cells were more sensitive to DOX than control cells | [28][31] |
| miR223 | Downregulated in HCC patient sera and liver biopsies | Through its binding to the 3´UTR of *ABCB1* gene, it specifically downregulated P-gp expression | miR223 overexpression increased sensitivity to DOX and paclitaxel in SMMC-7721 and HepG2 cells | [34][35] |
| miR491-3p | Downregulated in HCC tissues and in human cell lines (Hep3B, Bel-7402 and SMMC-7721 cells) | Negatively correlated with P-gp expression. Through its binding to the 3´UTR of *ABCB1* gene, it specifically downregulated P-gp expression and increased DOX intracellular concentration. Also, miR491-3p downregulated SP3 expression (transcription factor suggested to induce P-gp expression). | Conferred sensitivity to DOX and vinblastine in Hep3B and SMMC-7721 HCC cells | [38] |
| miR183 | Overexpressed in liver tissues and in drug-resistant Bel-7402 cells | Positively correlated with P-gp and MRP2 protein expression | Conferred resistance to 5-FU in Bel-7402 cells | [42][41] |

miRNA: microRNA; ABC: ATP-binding cassette; HCC: Hepatocellular carcinoma; DOX: Doxorubicin; 5-FU: 5-Fluoroacil; P-gp/*ABCB1*:P-glycoprotein; MRP1/*ABCC1*: Multidrug resistance-associated protein 1; 3´-UTR: 3´-untranslated region; MRP2: Multidrug resistance-associated protein 2.

**Table 2 miRNAs and autophagy in hepatocellular carcinoma cell drug resistance**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **miRNA** | **Expression Level in HCC** | **Effect on autophagy** | **Involvement in drug resistance** | **Ref.** |
| miR26a/b | Downregulated in tissues and cell lines (HepG2, Hep3B, MHCC97-H and SMCC-7721), also by chemotherapeutic drugs and autophagy inhibitors | Inhibited autophagy, by targeting the expression of ULK1, the key initiator of autophagy | Sensitized HepG2 cells and tumors to apoptosis induced by DOX through targeting autophagy | [53][54] |
| miR199a-5p | Downregulated in HepG2 and HuH-7 cells and tissues, also by chemotherapeutic drugs | Inhibited cisplatin-induced autophagy, by interacting with the 3´UTR region of ATG7 transcript(an autophagy related gene) | Protected HepG2 and HuH-7 cells from cisplatin-induced resistance | [56][58] |
| miR101 | Downregulated in cell lines (SMMC-7721, HepG2, Bel-4404, and97L) and tissues, associated with distant metastasis and related to poor prognosis | Inhibited autophagy, by reducing STMN1, RAB5A, ATG4D and mTOR expression (involved in the phagosome formation) | Sensitized HepG2 cells to apoptosis induced by cisplatin | [61][62] |
|
| miR216b | Downregulated in patient plasma and tissues, related to poor prognosis | Inhibited autophagy, by targeting . *MALAT1* (an oncogenic long non-coding RNA generally upregulated in HCC that modulates chemosensitivity) | Sensitized BEL-7402/5-FU resistant cells to 5-FU-, DOX- and mitomycin-induced death | [65][66] |
| miR142-3p | Downregulated in tissues, also by sorafenib treatment | Inhibited sorafenib-induced autophagy by binding to the 3´-UTR of ATG5 and ATG16L1 | Sensitized SMCC-7721 and HepG2 cells to sorafenib-induced death | [69][70] |
| miR21 | Overexpressed in patient tissues and in drug-resistant cells | Inhibited autophagy, and downregulated PTEN pathway | miR21-dependent autophagy inhibition contributed to sorafenib resistance in Huh7 and HepG2 cells and HCC tumors developed in mice | [74][72][73] |
| miR423-5p | Overexpressed in tissues, also elevated in serum of sorafenib-treated patients, and secreted in high levels from sorafenib-treated cells | Induced autophagy | Proposed as a helpful tool to predict patient response to sorafenib treatment | [77][78] |

miRNA: microRNA; HCC: Hepatocellular carcinoma; ULK1: Unc-51 like autophagy activating kinase; DOX: Doxorubicin; 3’-UTR: 3’-untranslated region; ATG: autophagy-related protein; STMN1: Stathmin 1; RAB5A: RAS related protein; ATG4D: autophagy-related 4D cysteine peptidase; mTOR: The mammalian target of rapamycin; *MALAT1*: metastasis associated lung adenocarcinoma transcript 1; 5-FU: 5-Fluoroacil; PTEN: phosphatase and tensin homologue.